555 related articles for article (PubMed ID: 26131937)
1. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.
Krönke J; Fink EC; Hollenbach PW; MacBeth KJ; Hurst SN; Udeshi ND; Chamberlain PP; Mani DR; Man HW; Gandhi AK; Svinkina T; Schneider RK; McConkey M; Järås M; Griffiths E; Wetzler M; Bullinger L; Cathers BE; Carr SA; Chopra R; Ebert BL
Nature; 2015 Jul; 523(7559):183-188. PubMed ID: 26131937
[TBL] [Abstract][Full Text] [Related]
2. Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase.
Petzold G; Fischer ES; Thomä NH
Nature; 2016 Apr; 532(7597):127-30. PubMed ID: 26909574
[TBL] [Abstract][Full Text] [Related]
3.
Fink EC; McConkey M; Adams DN; Haldar SD; Kennedy JA; Guirguis AA; Udeshi ND; Mani DR; Chen M; Liddicoat B; Svinkina T; Nguyen AT; Carr SA; Ebert BL
Blood; 2018 Oct; 132(14):1535-1544. PubMed ID: 30064974
[TBL] [Abstract][Full Text] [Related]
4. The novel mechanism of lenalidomide activity.
Fink EC; Ebert BL
Blood; 2015 Nov; 126(21):2366-9. PubMed ID: 26438514
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs.
Fuchs O
Cardiovasc Hematol Disord Drug Targets; 2019; 19(1):51-78. PubMed ID: 29788898
[TBL] [Abstract][Full Text] [Related]
6. The molecular mechanism of thalidomide analogs in hematologic malignancies.
Lindner S; Krönke J
J Mol Med (Berl); 2016 Dec; 94(12):1327-1334. PubMed ID: 27492707
[TBL] [Abstract][Full Text] [Related]
7. A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes.
Fang J; Liu X; Bolanos L; Barker B; Rigolino C; Cortelezzi A; Oliva EN; Cuzzola M; Grimes HL; Fontanillo C; Komurov K; MacBeth K; Starczynowski DT
Nat Med; 2016 Jul; 22(7):727-34. PubMed ID: 27294874
[TBL] [